IP Library Granted Patent US 10,508,077
Granted Patent B2
US 10,508,077 · App. 16/387,937 · Granted Dec 17, 2019

Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

Inventors: Kenneth W. Bair (Wellesley, MA); Nicholas Barczak (Waterford, CT); Bingsong Han (Westwood, MA); David R. Lancia, Jr. (Boston, MA); Cuixian Liu (Madison, CT); Matthew W. Martin (Arlington, MA); Pui Yee Ng (Waltham, MA); Aleksandra Rudnitskaya (Roslindale, MA); Jennifer R. Thomason (Clinton, MA); Mary-Margaret Zablocki (Revere, MA); Xiaozhang Zheng (Lexington, MA)
Assignee: FORMA Therapeutics, Inc.
C07C259/06A61K31/185A61K31/277A61K31/397A61K31/407A61K31/4035A61K31/417A61K31/4184A61K31/435A61K31/438A61K31/44A61K31/4439A61K31/451A61K31/495A61K31/5377C07D207/10C07D207/267C07D209/08C07D209/42C07D209/44C07D209/46C07D211/16C07D211/58C07D213/56C07D213/65C07D213/75C07D213/81C07D215/12C07D221/20C07D231/14C07D231/18C07D233/36C07D233/38C07D233/68C07D235/14C07D235/30C07D239/20C07D239/22C07D241/08C07D241/12C07D249/18C07D257/04C07D261/18C07D277/56C07D295/155C07D295/192C07D307/68C07D317/68C07D333/70C07D401/04C07D401/12C07D401/14C07D405/12C07D409/04C07D409/12C07D417/04C07D417/12C07D471/04C07D471/10C07D487/04C07D487/08C07D487/10C07D491/10C07D493/08C07D495/10C07D498/04C07D513/10Y02A50/393Y02A50/411Y02A50/481
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,508,077
App. No.
16/387,937
Granted
Dec 17, 2019
Kind
B2
Abstract

The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

Claims (39)

1. A compound of Formula (Ia):

or a pharmaceutically acceptable salt thereof,

wherein

A is hydrogen;

het is a 3-to-12 membered heterocycle, wherein said heterocycle is optionally substituted with one or more R d ;

each R d is independently hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, cyano, oxo, C 3 -C 8 cycloalkyl, 3-to-12 membered heterocycloalkyl, aryl, heteroaryl, —(CH 2 ) n R e , —(CH 2 ) n O(CH 2 ) m R e , —(CH 2 ) n NR e R f , —C(O)(CH 2 ) n R e , —(CH 2 ) n C(O)OR e , —C(O)(CH 2 ) n SR e , —(CH 2 ) n C(O)NR e R f , —NH(CH 2 ) n R e , —NHC(O)(CH 2 ) n R e , —NHC(O)(CH 2 ) n OR e , —NHC(O)(CH 2 ) n SR e , —NHS(O) 2 R e , —OR e , or —S(O) 2 R e , wherein each alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R e or R f ;

or two R d when attached to the same carbon atom can form a C 5 -C 12 spirocycle or a 3- to 12-membered spiroheterocycle, wherein the spirocycle or the spiroheterocycle are optionally substituted with one or more R e or R f ;

each R e is independently hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —C(O)(CH 2 ) n R f , or —(CH 2 ) n C(O)R f , wherein each alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R f ;

each R f is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, cyano, oxo, cycloalkyl, 3-to-12 membered heterocycloalkyl, aryl, heteroaryl, (C 1 -C 6 )alkylaryl, halogen, —(CH 2 ) n O(CH 2 ) m CH 3 , —(CH 2 ) n N(CH 3 ) 2 , —(CH 2 ) n O(CH 2 ) m N(CH 3 ) 2 , —(CH 2 ) n NR e R f , —N(CH 3 )S(O) 2 CH 3 , —S(CH 2 ) m CH 3 , or —S(O) 2 (CH 2 ) m CH 3 , wherein each alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, oxo, halogen, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

n is 0, 1, 2, 3, or 4; and

m is 0, 1, 2, 3, or 4.

2. The compound of claim 1 , wherein

each R d is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, oxo, C 3 -C 8 cycloalkyl, 3-to-12 membered heterocycloalkyl, aryl, heteroaryl, or —(CH 2 ) n R e , wherein each alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R e or R f ;

or two R d when attached to the same carbon atom can form a 3- to 12-membered spiroheterocycle wherein the spiroheterocycle is optionally substituted with one or more R e or R f .

3. The compound of claim 2 , wherein each R e is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, or heterocycloalkyl, wherein each alkyl, alkoxy, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R f .

4. The compound of claim 3 , wherein each R f is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, cycloalkyl, 3- to 12-membered heterocycloalkyl, or halogen.

5. The compound of claim 1 , wherein het is imidazolidin-2-one substituted with one or more R d .

6. The compound of claim 5 , wherein

each R d is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, oxo, C 3 -C 8 cycloalkyl, 3-to-12 membered heterocycloalkyl, aryl, heteroaryl, or —(CH 2 ) n R e , wherein each alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R e or R f ;

or two R d when attached to the same carbon atom can form a 3- to 12-membered spiroheterocycle wherein the spiroheterocycle is optionally substituted with one or more R e or R f .

7. The compound of claim 6 , wherein each R e is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, or heterocycloalkyl, wherein each alkyl, alkoxy, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R f .

8. The compound of claim 7 , wherein each R f is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, cycloalkyl, 3- to 12-membered heterocycloalkyl, or halogen.

9. The compound of claim 5 , wherein

each R d is independently C 1 -C 6 haloalkyl, oxo, C 3 -C 8 cycloalkyl, or 3-to-12 membered heterocycloalkyl, wherein each haloalkyl, alkoxy, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R e or R f .

10. The compound of claim 9 , wherein each haloalkyl, alkoxy, cycloalkyl, or heterocycloalkyl of R d is optionally substituted with one or more R e , wherein each R e is independently C 1 -C 6 alkoxy.

11. The compound of claim 9 , wherein each haloalkyl, alkoxy, cycloalkyl, or heterocycloalkyl of R d is optionally substituted with one or more R f , wherein each R f is independently C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, or halogen.

12. The compound of claim 1 , wherein het is 1,3-dihydro-2H-benzo[d]imidazole-2-one substituted with one or more R d .

13. The compound of claim 12 , wherein

each R d is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, oxo, C 3 -C 8 cycloalkyl, 3-to-12 membered heterocycloalkyl, aryl, heteroaryl, or —(CH 2 ) n R e , wherein each alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R e or R f ;

or two R d when attached to the same carbon atom can form a 3- to 12-membered spiroheterocycle wherein the spiroheterocycle is optionally substituted with one or more R e or R f .

14. The compound of claim 13 , wherein each R e is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, or heterocycloalkyl, wherein each alkyl, alkoxy, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more R f .

15. The compound of claim 14 wherein each R f is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, cycloalkyl, 3- to 12-membered heterocycloalkyl, or halogen.

16. The compound of claim 12 , wherein each R d is independently C 1 -C 6 alkyl, oxo, or C 3 -C 8 cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more R e or R f .

17. The compound of claim 16 , wherein each R e is independently C 1 -C 6 alkyl.

18. The compound of claim 12 , wherein

each R d is independently C 1 -C 6 alkyl, oxo, or C 3 -C 8 cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more R e or R f ;

or two R d when attached to the same carbon atom can form a 3- to 12-membered spiroheterocycle.

19. The compound of claim 18 , wherein each R e is independently C 1 -C 6 alkyl or C 1 -C 6 alkoxy.

20. The compound of claim 18 , wherein each R f is independently C 1 -C 6 haloalkyl or halogen.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 17, 2023
From: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
To: VALO HEALTH, INC.; VALO HEALTH, LLC
Reel/Frame 065255/0660 →
SECURITY INTEREST Recorded Jul 6, 2023
From: VALO HEALTH, LLC; VALO HEALTH, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
Reel/Frame 064207/0957 →
MERGER Recorded Sep 8, 2021
From: VALO EARLY DISCOVERY, INC.
To: VALO HEALTH, INC.
Reel/Frame 057438/0025 →
CHANGE OF NAME Recorded Sep 16, 2020
From: INTEGRAL EARLY DISCOVERY, INC.
To: VALO EARLY DISCOVERY, INC.
Reel/Frame 053787/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2020
From: FORMA THERAPEUTICS, INC.
To: INTEGRAL EARLY DISCOVERY, INC.
Reel/Frame 053402/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2019
From: BAIR, KENNETH W.; BARCZAK, NICHOLAS; HAN, BINGSONG; LANCIA, DAVID R., JR; LIU, CUIXIAN; MARTIN, MATTHEW W.; NG, PUI YEE; RUDNITSKAYA, ALEKSANDRA; THOMASON, JENNIFER R.; ZABLOCKI, MARY MARGARET; ZHENG, XIAOZHANG
To: FORMA THERAPEUTICS, INC.
Reel/Frame 049957/0528 →
Continuity (7)
Continuation 15925559 · Mar 19, 2018
Continuation 15688732 · Aug 28, 2017
Continuation 15067605 · Mar 11, 2016
Provisional Application 62270371 · Dec 21, 2015
Provisional Application 62184335 · Jun 25, 2015
Provisional Application 62132895 · Mar 13, 2015
Related Publication 20190241506A1 · Aug 8, 2019